This trial aimed to ascertain the effects of nano‐curcumin as an anti‐inflammatory agent and a cystic fibrosis transmembrane conductance regulator modulator on clinical and inflammatory markers in children with cystic fibrosis (CF). The gene discussed is CFTR; the disease is cystic fibrosis.